Methylphenidate transdermal system: Clinical applications for attention-deficit/hyperactivity disorder

Expert Review of Clinical Pharmacology

Volumn 4, Issue 3, 2011, Pages 311-328

  Elia, Josephine ^a,b   Wilson, Zoe ^a   La Porta, Lilly Sehgal ^a   Algon, Sibel A ^a   Prowler, Matthew L ^a   Cartwright, Shanique T ^a   Mckenna, Patricia A ^a   Laracy, Seth ^a   Takeda, Toshinobu ^a,c   Borgmann Winter, Karin ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c RYUKOKU UNIVERSITY   (Japan)

Author keywords

ADHD; methylphenidate transdermal system; pharmacotherapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FENTANYL; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO;

ABDOMINAL PAIN; AGGRESSION; ANGER; ANKLE FRACTURE; ANOREXIA; APPLICATION SITE DISCOMFORT; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CONFUSION; CONTACT DERMATITIS; CONTUSION; COUGHING; CRYING; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EPIDERMIS HYPERPLASIA; ERYTHEMA; FATIGUE; GENETIC VARIABILITY; HEART PALPITATION; HEART RATE; HUMAN; HYPERKERATOSIS; HYPERTENSION; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; NONHUMAN; NOSE CONGESTION; OSMOTIC PUMP; PARANOIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRURITUS; QUALITY OF LIFE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN MANIFESTATION; SKIN PIGMENTATION; SLEEP DISORDER; SORE THROAT; STOMACH PAIN; SUICIDE ATTEMPT; SYNCOPE; TACHYCARDIA; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; HUMANS; METHYLPHENIDATE;

EID: 79955946140     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.11     Document Type: Article

References (117)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition).American Psychiatric Publishing Inc., VA, USA (2004).
2. Martel M, Nikolas M, Nigg JT. Executive function in adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 46(11), 1437-1444 (2007). (Pubitemid 351338964)
3. Sonuga-Barke EJ, Sergeant JA, Nigg J, Willcutt E. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: nosologic and diagnostic implications. Child. Adolesc. Psychiatr. Clin. N. Am. 17(2), 367-384, ix (2008). (Pubitemid 351265398)
4. Engelhardt PE, Nigg JT, Carr LA, Ferreira F. Cognitive inhibition and working memory in attention-deficit/ hyperactivity disorder. J. Abnorm. Psychol. 117(3), 591-605 (2008).
5. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 164(6), 942-948 (2007). (Pubitemid 46972911)
6. Polanczyk G, Jensen P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child. Adolesc. Psychiatr. Clin. N. Am. 17(2), 245-260, vii (2008). (Pubitemid 351265397)
7. Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry 190, 402-409 (2007). (Pubitemid 46706952)
8. Strine TW, Lesesne CA, Okoro CA et al. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev. Chronic Dis. 3(2), A52 (2006).
9. Xiang H, Stallones L, Chen G, Hostetler SG, Kelleher K. Nonfatal injuries among US children with disabling conditions. Am. J. Public Health 95(11), 1970-1975 (2005). (Pubitemid 41572372)
10. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA 285(1), 60-66 (2001). (Pubitemid 32042717)
11. Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J. Nerv. Ment. Dis. 188(4), 230-234 (2000). (Pubitemid 30210864)
12. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 92(2), 212-218 (1993). (Pubitemid 23226834)
13. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 98(6 Pt 1), 1089-1095 (1996). (Pubitemid 26399271)
14. Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid. Anal. Prev. 39(1), 94-105 (2007). (Pubitemid 44633822)
15. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am. J. Psychiatry 155(4), 493-498 (1998). (Pubitemid 28207444)
16. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry 50(7), 565-576 (1993). (Pubitemid 23203567)
17. Weiss G, Hechtman L. Hyperactive Children Grown Up (2nd Edition): ADHD in Children, Adolescents and Adults. Guilford Press, NY, USA (1993).
18. Barkley R. Attention-Defict/Hyperactivity Disorder. A Clinical Workbook. Guilford Press, NY, USA (1998).
19. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J. Am. Acad. Child. Adolesc. Psychiatry 45(2), 192-202 (2006). (Pubitemid 43151524)
20. Biederman J, Monuteaux MC, Doyle AE et al. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J. Consult. Clin. Psychol. 72(5), 757-766 (2004). (Pubitemid 39299438)
21. Maedgen JW, Carlson CL. Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes. J. Clin. Child Psychol. 29(1), 30-42 (2000).
22. Kessler RC, Adler L, Ames M et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J. Occup. Environ. Med. 47(6), 565-572 (2005). (Pubitemid 40847440)
23. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J. Subst. Abuse 7(3), 373-378 (1995). (Pubitemid 26032582)
24. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol. Psychiatry 44(4), 269-273 (1998). (Pubitemid 28389712)
25. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 36(1), 37-44 (1997). (Pubitemid 27024226)
26. Humfleet GL, Prochaska JJ, Mengis M et al. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob. Res. 7(3), 453-460 (2005). (Pubitemid 41418718)
27. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J. Learn. Disabil. 31(6), 533-544 (1998).
28. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am. J. Addict. 6(3), 205-217 (1997). (Pubitemid 27356003)
29. Banaschewski T, Coghill D, Santosh P et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur. Child. Adolesc. Psychiatry 15(8), 476-495 (2006). (Pubitemid 46020533)
30. Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc).46(5), 299-314 (2010).
31. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/ hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 50(2), 171-179 (2011).
32. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 108(4), 1033-1044 (2001).
33. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 46(7), 894-921 (2007).
34. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann. Clin. Psychiatry 22(3), 196-204 (2010).
35. Bradley C. The behavior of children receiving benzedrine. Am. J. Psychiatry 94, 577-585 (1937).
36. Hosenbocus S, Chahal R. A review of long-acting medications for ADHD in Canada. J. Can. Acad. Child Adolesc. Psychiatry. 18(4), 331-339 (2009).
37. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur. Child Adolesc. Psychiatry 19(4), 325-340 (2010).
38. Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry 60(2), 204-211 (2003). (Pubitemid 36173129)
39. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110(2 Pt 1), 258-266 (2002). (Pubitemid 34833008)
40. McGough JJ, Biederman J, Greenhill LL et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J. Am. Acad. Child. Adolesc. Psychiatry 42(6), 684-691 (2003). (Pubitemid 39625054)
41. Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (the Comacs Study).Pediatrics 113(3 Pt 1), e206-e216 (2004).
42. Tuerck D, Wang Y, Maboudian M, Sedek G, Pommier F, Appel-Dingemanse S. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int. J. Clin. Pharmacol. Ther. 45(12), 662-668 (2007). (Pubitemid 350268041)
43. Blick SK, Keating GM. Lisdexamfetamine. Paediatr. Drugs 9(2), 129-135 (2007). (Pubitemid 46624566)
44. Volkow ND, Wang G, Fowler JS et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21(2), RC121 (2001).
45. Volkow ND, Wang GJ, Kollins SH et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302(10), 1084-1091 (2009).
46. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68(5), 2032-2037 (1997). (Pubitemid 27176139)
47. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681-698 (2007).
48. Adriani W, Leo D, Guarino M et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann. NY Acad. Sci. 1074, 52-73 (2006). (Pubitemid 44532810)
49. Brandon CL, Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 18(6), 1584-1592 (2003). (Pubitemid 37215111)
50. Parma DL, Benasayag SJ, Szijan I. Expression of c-myc and c-fos oncogenes in different rat brain regions during postnatal development. Int. J. Dev. Neurosci. 9(6), 613-619 (1991).
51. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 17(21), 8491-8497 (1997). (Pubitemid 27461070)
52. Li Y, Kolb B, Robinson TE. The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen. Neuropsychopharmacology 28(6), 1082-1085 (2003).
53. Boikess SR, Marshall JF. A sensitizing d-amphetamine regimen induces long-lasting spinophilin protein upregulation in the rat striatum and limbic forebrain. Eur. J. Neurosci. 28(10), 2099-2107 (2008).
54. Boikess SR, O'Dell SJ, Marshall JF. A sensitizing d-amphetamine dose regimen induces long-lasting spinophilin and VGLUT1 protein upregulation in the rat diencephalon. Neurosci. Lett. 469(1), 49-54 (2010).
55. Penner MR, McFadyen MP, Pinaud R, Carrey N, Robertson HA, Brown RE. Age-related distribution of c-fos expression in the striatum of CD-1 mice after acute methylphenidate administration. Brain Res. Dev. Brain Res. 135(1-2), 71-77 (2002). (Pubitemid 34442491)
56. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl Acad. Sci. USA 93(24), 14128-14133 (1996). (Pubitemid 26424257)
57. Yin HS, Chen K, Shih JC, Tien TW. Down-regulated GABAergic expression in the olfactory bulb layers of the mouse deficient in monoamine oxidase B and administered with amphetamine. Cell. Mol. Neurobiol. 30(4), 511-519 (2010).
58. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5), 699-711 (2002). (Pubitemid 35335888)
59. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 71(6), 754-763 (2010).
60. Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann. Pharmacother. 40(6), 1134-1142 (2006). (Pubitemid 43886972)
61. Newcorn JH, Kratochvil CJ, Allen AJ et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am. J. Psychiatry. 165(6), 721-730 (2008). (Pubitemid 351810541)
62. Bangs ME, Jin L, Zhang S et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 31(4), 345-354 (2008). (Pubitemid 351441582)
63. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 46(2), 242-251 (2007). (Pubitemid 46148423)
64. Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav. Brain Funct. 4, 12 (2008).
65. Wang M, Ramos BP, Paspalas CD et al. a2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129(2), 397-410 (2007). (Pubitemid 46574970)
66. Biederman J, Melmed RD, Patel A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121(1), e73-e84 (2008).
67. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 13(12), 1047-1055 (2008).
68. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr. Med. Res. Opin. 26(4), 977-989 (2010).
69. Brams M, Moon E, Pucci M, Lopez FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr. Med. Res. Opin. 26(8), 1809-1825 (2010).
70. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry 159(11), 1896-1901 (2002). (Pubitemid 35283256)
71. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J. Am. Acad. Child. Adolesc. Psychiatry 48(2), 155-165 (2009).
72. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 8(4), 4 (2006).
73. Elia J, Gai X, Xie HM et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol. Psychiatry 15(6), 637-646 (2010).
74. Neale BM, Medland SE, Ripke S et al. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 49(9), 884-897 (2010).
75. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children and adolescents. Child Adolesc. Psychiatry Ment. Health 2(1), 15 (2008).
76. Jensen PS, Hinshaw SP, Kraemer HC et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child Adolesc. Psychiatry 40(2), 147-158 (2001). (Pubitemid 32111018)
77. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 23(9), 739-753 (2009).
78. Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr. Med. Res. Opin. 18(5), 311-316 (2002). (Pubitemid 35014548)
79. Haffey MB, Buckwalter M, Zhang P et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad. Med. 121(5), 11-19 (2009).
80. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD), effects of ADHD and psychiatric comorbidity. Am. J. Psychiatry. 152(11), 1652-1658 (1995).
81. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111(1), 179-185 (2003). (Pubitemid 36071051)
82. Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child. Adolesc. Psychiatry 47(1), 21-31 (2008).
83. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J. Med. 10(5), 111 (2008).
84. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr. Dis. Treat. 6, 317-327 (2010).
85. Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad. Med. 122(5), 35-41 (2010).
86. Miller TR, Milicic I, Bauch J et al. Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br. J. Pharmacol. 157(1), 139-149 (2009).
87. Jin L, Xu W, Kielbasa W, Quinian T, Kauffman L, Allen A. Safety and efficacy of LY2216684 in an open-label study in pediatric patients with ADHD. Presented at: The 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY, USA, 26-31 October 2010.
88. Shire Pharmaceuticals. Daytrana® prescribing information (2010).
89. Pierce D, Dixon CM, Wigal SB, McGough JJ. Pharmacokinetics of methylphenidate transdermal system (MTS), results from a laboratory classroom study. J. Child Adolesc. Psychopharmacol. 18(4), 355-364 (2008).
90. Zhu HJ, Patrick KS, Yuan HJ et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82(6), 1241-1248 (2008).
91. Zhu QG, Hu JH, Zeng HW. [Stereoselectivity of skin carboxylesterase metabolism]. Yao Xue Xue Bao 40(4), 322-326 (2005).
92. Patrick KS, Straughn AB, Perkins JS, Gonzalez MA. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum. Psychopharmacol. 24(1), 1-17 (2009).
93. Paut O, Camboulives J, Viard L, Lemoing JP, Levron JC. Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. Anaesthesia 55(12), 1202-1207 (2000).
94. Pierce D, Martin P, Katic A, Buckwalter M, Webster K. Pharmacokinetics of methylphenidate transdermal system and osmotic-release oral system methylphenidate in children and adolescents with ADHD. Presented at: American Academy of Child and Adolescent Psychiatry 56th Annual Meeting. Honolulu, Hawaii, 27 October-1 November 2009.
95. Gonzalez MA, Campbell D, Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/ hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 19(3), 227-232 (2009).
96. Lefevre G, Sedek G, Huang HL et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol. 47(4), 471-478 (2007). (Pubitemid 46465956)
97. Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20(9), 713-738 (2006). (Pubitemid 44373701)
98. Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. 52(5), 561-568 (1992).
99. Findling RL, Bukstein OG, Melmed RD et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/ hyperactivity disorder. J. Clin. Psychiatry 69(1), 149-159 (2008). (Pubitemid 351282009)
100. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J. Atten. Disord. 9(3), 476-485 (2006). (Pubitemid 43171141)
101. Wilens TE, Boellner SW, Lopez FA et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 47(6), 700-708 (2008).
102. Pelham WE Jr, Manos MJ, Ezzell CE et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 44(6), 522-529 (2005). (Pubitemid 40720951)
103. Pelham WE Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B. Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J. Consult. Clin. Psychol. 61(3), 506-515 (1993). (Pubitemid 23179704)
104. Pelham WE, Burrows-Maclean L, Gnagy EM et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp. Clin. Psychopharmacol. 13(2), 111-126 (2005). (Pubitemid 40791820)
105. Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, Li Y. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr. 15(7), 419-430 (2010).
106. Findling RL, Wigal SB, Bukstein OG et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, Phase III extension of four clinical trials. Clin. Ther. 31(8), 1844-1855 (2009).
107. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J. Child Adolesc. Psychopharmacol. 19(6), 673-681 (2009).
108. Arnold LE, Bozzolo DR, Hodgkins P et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr. Med. Res. Opin. 26(1), 129-137 (2010).
109. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(8), 1412-1418 (2008).
110. Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr. Med. Res. Opin. 25(12), 3001-3010 (2009).
111. Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc. Psychiatry Ment. Health 3(1), 39 (2009).
112. McCormick CG, Henningfield JE, Haddox JD et al. Case histories in pharmaceutical risk management. Drug Alcohol Depend. 105(Suppl. 1), S42-S55 (2009).
113. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J. Atten. Disord. 12(4), 308-315 (2009).
114. Fowler JF, Warshaw EM, Squires L. Methylphenidate patch-test protocol and irritancy threshold determination in healthy adult subjects. Dermatitis 20(5), 271-274 (2009).
115. Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J. Am. Acad. Child. Adolesc. Psychiatry 46(9), 1138-1147 (2007). (Pubitemid 47295925)
116. Arnold LE, Lindsay RL, Lopez FA et al. Treating attention-deficit/ hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 120(5), 1100-1106 (2007). (Pubitemid 350085550)
117. Hess EJ. The use of transgenes and mutations in the mouse to study the genetic basis of locomotor hyperactivity. Methods 10(3), 374-383 (1996). (Pubitemid 26391936)